Long-term safety and efficacy of twice-yearly depemokimab in type 2 asthma with an eosinophilic phenotype: 2-year integrated analysis of the phase 3a SWIFT-1 and SWIFT-2 studies and AGILE open-label extension

The Lancet Respiratory Medicine · Elsevier

Аннотация

Publication date: Available online 29 October 2026 Source: The Lancet Respiratory Medicine Author(s): Michael E Wechsler, Paul E Pfeffer, David I Bernstein, Ruchong Chen, Toshiyuki Koya, David J Jackson, Ian D Pavord, Pascal Chanez, Arnaud Bourdin, Diana Jarreta, David Muccino, Claire Tacon, Anna Vichiendilokkul, Chang-Qing Zhu, Daniel J Jackson

Читать у издателя →

Похожие статьи